Alnylam Pharma (ALNY) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $161.08 --0%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
SENEA, XFOR, MG, More
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
SENEA, XFOR, MG, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.07), $0.11 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $9.1 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Frontdoor, Inc. (FTDR) Tops Q3 EPS by 4c ; Offers Guidance
- Zoetis (ZTS) Tops Q3 EPS by 24c; offers guidance
- Axcelis Technologies (ACLS) Tops Q3 EPS by 22c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
